FDA Recommendations for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions
Learn what FDA expects in a predetermined change control plan for AI/ML-enabled device software and when a model change needs a new marketing submission.
Speaker
Rachelle D Souza
Regulatory affairs consultant · In regulatory compliance since 2007
Overview
AI is expected to change healthcare, but it brings risks around ethical data use, biased algorithms, patient safety and cybersecurity. FDA has started overseeing AI/ML-enabled device software functions, and its recommendations center on a predetermined change control plan (PCCP) in the marketing submission.
This 75-minute webinar explains what a PCCP is and what it should contain: the types of modifications to include, the modification protocol, traceability and impact assessment for changes to machine learning models and algorithms.
You'll also look at data management and retraining practices, performance evaluation protocols and update procedures. Device examples and hypothetical scenarios show when a model change stays within an authorized PCCP and when a new marketing submission is needed.
Why attend: A growing number of AI/ML-enabled devices, many in radiology, have FDA authorization. Manufacturers that anticipate post-approval changes in an authorized PCCP don't need a new submission for those changes, which saves time and cost. The session suits regulatory affairs professionals, engineers, developers, executives and founders at AI and medical device companies, as well as researchers and students who want to understand FDA's expectations and the AI Bill of Rights.
What’s covered
- Machine learning, AI and AI/ML device software functions
- The AI Bill of Rights and design and development considerations for AI/ML software
- Marketing submission considerations for an FDA-recommended predetermined change control plan (PCCP)
- Types of modifications to include in a PCCP
- PCCP contents
- Modification protocol, traceability and impact assessment for changes to ML models and algorithms
- Data management, retraining, performance evaluation protocols and update procedures
- Device examples and hypothetical scenarios: compliant modifications vs a new marketing submission
Who should attend
What you get
About the speaker
Rachelle D’Souza began her career in regulatory compliance in 2007. She has provided Regulatory Affairs, Quality Assurance, Clinical, Pharmacovigilance and Medical Information support to the Pharmaceutical, Biologic, Generic, Natural Health Product, Dietary Supplement, Medical Device, Cosmetic, Pesticide and Food industries.
Rachelle has developed regulatory strategies, independently prepared regulatory submissions and secured product and site approvals from global regulatory agencies. She has also designed, implemented, and maintained global quality, pharmacovigilance and medical information systems. Rachelle’s regulatory articles and webinars on the latest global
regulatory developments have been published in print and online by regulatory professional associations, webinar hosting platforms and industry magazines.
More in FDA Compliance
See all 46 FDA webinars →
Carolyn Troiano · 90 min
Excel Spreadsheets; Develop and Validate for 21 CFR Part 11 Compliance
David Nettleton · 75 min
Major cGMP Issues: FDA Concerns in 2026
Ms. Michael Redmond · 60 min
Performance of Root Cause Analysis, CAPA, and Effectiveness Checks
Meredith Crabtree · 90 min